Cutaneous lupus erythematosus (CLE) is a chronic autoimmune condition that encompasses several subtypes with varying morphologies but a shared pathogenesis and cytokine signature.1,2 CLE is often isolated to the skin; an additional 70% to 80% of patients with systemic lupus erythematosus (SLE) suffer from CLE during their disease course.3,4 Given its potential for permanent scarring and dyspigmentation, CLE carries a significant negative impact on quality of life.5,6 Management of CLE subtypes has traditionally consisted of preventive measures alongside combinations of topical and systemic immunosuppressive therapies.
No takes yet. Share an insight, caveat, or question.
Kowalski et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: